Aurobindo Pharma Shares in Focus; Subsidiary CuraTeQ Biologics Receives ANVISA Approval for Hyderabad Facility

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has secured GMP approval from ANVISA, Brazil's National Health Surveillance Agency, as per the exchange filings. 

The approval covers the company's biosimilars manufacturing facility in Hyderabad, strengthening its regulatory footprint in international markets.  

Facility Cleared After GMP Inspection 

The Hyderabad facility underwent a GMP inspection conducted by ANVISA between May 11 and May 15, 2026. 

Approval was granted following the successful inspection of the facility for biological API and sterile products manufacturing.  

Inspection Covered Multiple Operations 

The inspection assessed 4 biosimilar products along with the mammalian and microbial drug substance manufacturing facilities. 

It also covered the prefillable syringe and vial filling facilities, packaging and labelling operations, as well as quality control testing and product release laboratories.  

Expands Presence in Latin America 

CuraTeQ's drug substance and drug product GMP facility already holds certifications from the European Medicines Agency (EMA) and the World Health Organization (WHO).

According to the company, the ANVISA approval reaffirms its commitment to global quality standards and regulatory compliance while strengthening its ability to supply biosimilar products across Brazil and the broader Latin American market.  

Read More: Sun Pharma, Cipla and Other Pharma Shares Fall Up to 3% After Trump Announces 100-200% Tariffs on Generics Drugs from 2028! 

Aurobindo Pharma Share Price Performance  

As of 22 July 2026, at 11:00 AM, Aurobindo Pharma Limited share price was trading at ₹1,525.90 per share, reflecting a decline of 3.41% from the previous trading session. 

Conclusion 

The ANVISA approval marks another regulatory milestone for CuraTeQ Biologics, enhancing the global recognition of its Hyderabad manufacturing facility and supporting the company's expansion in the Brazilian and wider Latin American biosimilars market.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.